Wednesday Daily Dose 2018

The EAHP

Wednesday 21 March 2018

Daily dose

Information that makes you feel good!

23rd Congress March 2018 Gothenburg

Hospital pharmacists Show us what you can do!

CONGRESS AGENDA Full programme of activities

Page 2

KEYNOTE 1 PREVIEW Global health and infectious diseases: Advice by Helena Nordenstedt

KabiHelp Shaping Tomorrow in PN Compounding New PN Compounder from Fresenius Kabi

EAHP SURVEY

Live Demos Presented by KabiHelp Experts

Survey activities & results

Page 4

Page 8

Wednesday, 21 March 2018 11:00 | 14:00 | 16:30 | 19:00 Thursday, 22 March 2018 11:00 | 14:15 | 17:00

Welcome to the EAHP Daily Dose! Available hot off the press on Wednesday and Thursday of the Congress, this newspaper will come in handy to plan your day or brush up on some important issues. From a mixture of preview articles of sessions and seminars, to interviews with some of the key people behind the Congress and ‘at a glance’ overviews of the day’s schedule: the EAHP Daily Dose is a must–read for all attendees!

r Visit ou ee s o t h Boot lp KabiHe

Friday, 23 March 2018 11:00

Welcome to our 23rd Congress! old and interesting buildings.

EAHP is pleased to have you at the 23 rd Congress of the EAHP 21– 23 March 2018 with the theme of “Hospital pharmacists – Show us what you can do!”.

The scientif ic program is well advanced and is relevant for you as a hospital pharmacist dealing with the challenges of economic restrictions and increased demands.

Joan Peppard EAHP President

Dear Colleagues, Welcome to Gothenburg, a beautiful city with an exciting cultural life and excellent restaurants with the old town area of narrow cobblestone streets, small stores with character and

This Congress provides an opportunity to demonstrate what hospital pharmacists have achieved, to provide inspiration for future development and to energise us for the road ahead. This opportunity to showcase the benefits facilitated by hospital pharmacists will influence decision makers, multidisciplinary team members and patients to demand hospital pharmacists’ full engagement in the

medication process.

EAHP’s annual Congress is the largest Congress for hospital pharmacy in Europe and is attended by pharmacists from all over the world. This Congress continues to provide you with an exceptional opportunity to meet, network and share expertise and best practice with colleagues while keeping up to date with the latest developments in hospital pharmacy. With all you have to see, learn and do during your visit I hope that we will have time to enjoy a fika together.

I am honoured as President of EAHP to welcome you to this Congress. Once again, thank you for attending! Have a wonderful time!

Joan Peppard – EAHP President

Meet the Expert!

TDPT-IL-00080

Dr. Paul Sessink Handling Antibiotics with Tevadaptor® Booth #48 (Hall B)

Tevadaptor® is scientifically validated with repeated proven performance

Wednesday, March 21st, 2018 12:00-13:00 17:00-18:00 Thursday, March 22nd, 2018 09:30-10:30 14:00-15:00

Visit our Booth #48 to view Antibiotics wipe testing results and elastomer integrity testing results

Poster Session (Hall A) During coffee breaks

www.tevadaptor.com

23rd Congress of the EAHP

2

WEDNESDAY, 21 MARCH 2018 DATE/TIME

MEETINGS/EVENTS

ROOM

07.00 – 17.00

Registration opens (individuals, groups and exhibitors)

Entrance No 2

08.30 – 10.15

Opening ceremony & Keynote 1 – A fact–based view on global health and infectious diseases H. Nordenstedt

Hall C

10.15

Exhibition opens

Hall B

10.15 – 11.45

Coffee break

Hall B

10.30 – 11.50

Award nominee oral presentations

A4

10.30 – 11.45

Good Practice Initiative oral presentations

A3

10.30 – 11.45

Other sessions Hospital pharmacy in Sweden, highlights and curiosities K–J. Lindner; U. Gillespie; A. Bergkvist

F5

10.45 – 11.15

Bayer – Meet the Expert

Hall B – Booth no 26

12.00 – 13.30

Synergy Satellite: Biosimilars in breast cancer – the next challenge (sponsored by an educational grant from Amgen) J. Goncalves; H. Rolighed Christensen; R. Bartsch

Hall C

13.30 – 14.30

Lunch

Hall B

13.45 – 14.15

Bayer – Meet the Expert

Hall B – Booth no 26

14.30 – 18.30

Student Programme: An evidence based approach to developing an individualised patient care plan A. Tonna; K. Gibson Smith

J1

14.30 – 16.00

Seminars Seminar IG1 – The efficient pharmacist – Prioritising tasks and designing processes R. Fernandes; A. Jacklin

F2+F3

Seminar SPD1 – Medicines shortages – A reality check?

T. Hoppe–Tichy; N. Linde–Laursen

F5

Seminar PC1 – Clinical trial regulation and ethical committees I. Krämer; C. M. Romeo Casabona

A3

Seminar PC3 – Hospital pharmacists involved in ATPM and in Risk Assessment A. De Goede; K. Saadat

G3

Seminar CPS1 – Managing polypharmacy – Thinking outside the box M. Wilson; C. Morrison

G1+G2

Seminar PQ2 – Ready to administer drugs – Is everything under control?

S. Sauer; O. Delgado Sánchez

A5

Workshop 2 – Assessment and clinical importance of pharmacist recommendations H. Toss; U. Gillespie

R2

Workshop 3 – Check of medication appropriateness (COMA): an instrument to implement clinical guidelines in practice T. Van Nieuwenhuyse; C. Quintens

R2

14.30 – 16.00

Synergy Interactive Session: Anticoagulation – from theory to practice (sponsored by an educational grant from Bayer) K. Malá; S. Steurbaut; B. van den Bemt

H1

14.30 – 16.00

Industry sponsored satellites Optel Group “The EU FMD for hospital pharmacies”

H2

BD “Your day–to–day challenge: drive efficiency and improve safety”

G4

16.00 – 17.00

Coffee break

Hall B

17.00 – 18.30

Seminars Seminar ER1 – Clinical Trials in Paediatric Haemato–oncology: different ways for HPs to participate M–B. Aretin; F. Engels

G3

23rd Congress of the EAHP

3

Seminar PC2 – Hospital mergers and the centralisation of production services A. Vermes; S. Crauste–Manciet

G1+G2

Seminar IG2 – The productive pharmacists – Process and workforce planning V. Zardet; M. Frachette

F5

Seminar SPD2 – Bridging the efficacy / effectiveness gap A. Gouveia; N. Groessmann

A3

Workshop 1 – The pharmacist’s role in the drugs and therapeutics committee N. Martinez–Lopez de Castro; H. Plet

J2

17.00 – 18.30

Synergy Satellite Session: Biosimilars in cancer care – the next challenge (financial support was provided by Pfizer Limited as a Medical and Educational Goods and Service) R. Giuliani; P. Cornes; G. Befrits

17.00 – 18.30

Industry sponsored satellites

H2

Pfizer “Pharmacoeconomic impact of serious infections: the role of the hospital pharmacist”

F4

18.30 – 20.00

Get together reception

Hall B

19.30 – 21.00

Poster walk. Join the Scientific Committee during their evaluation of the posters selected for the Poster Walk

Hall A

What to look out for at the congress Welcome to the 23rd Congress of the European Association of Hospital Pharmacists! This year’s Congress is dedicated to the theme of promoting the role and abilities of the hospital pharmacist.

By providing advocacy and communication tools, hospital pharmacists can engage hospital managers to deliver better services, helping them embrace connectivity and collaboration among various levels and roles of healthcare professionals, all to further benefit patient safety.

B

uilding on the success of preceding Congresses, this year’s programme offers a cross–section of topics to inspire your daily practice. From providing a comprehensive overview of ongoing pharmaceutical developments to unique presentations and events, this Congress gives you the opportunity to share novel ideas, start collaborations, and reach out to the largest gathering of hospital pharmacists in Europe!

pharmacist’s role in educating patients on their use, and novel projects for managing atrial fibrillation. Following suit, the Synergy Satellite ‘Biosimilars in cancer care– the next challenge’ (financial support was provided by Pfizer Limited as a Medical and Educational Goods and Service) will take place Wednesday at 17:00 and Thursday at 12:00 and will cover the upcoming market arrival of biosimilar cancer drugs and their relevance for patient care.

Programme highlights This year, EAHP presents a programme featuring three keynote presentations, five Synergy Satellite sessions, dozens of presentations and much more! With content created by our Scientific Committee, the Synergy Satellite sessions are accredited educational events that address topics which require continuous learning in our ever–changing world.

The first Synergy Satellite ‘Biosimilars in breast cancer– the next challenge’ (sponsored by an educationalal grant from Amgen) will take place on Wednesday 21st March at 12:00 and addresses the new frontier for biosimilars and breast cancer treatment, the facts supporting biosimilar approval in the EU and concerns arising from biosimilar trials.

We are also excited to provide you with two other Synergy Satellite sessions on Wednesday, which will be repeated on Thursday in case you couldn’t attend the first time around!

To begin with, the Synergy Satellite ‘Anticoagulation – from theory to practice’ (sponsored by an educationalal grant from Bayer) will take place Wednesday at 14:30 and Thursday at 9:00 and will address the differences between anticoagulants, their pharmacodynamics, and pharmacokinetics, the

For a fresh start to Thursday 23rd of March, the Synergy Satellite ‘The power of automation’ (sponsored by an educationalal grant from Omnicell) will begin at 7:30 and will focus on the opportunities, risks, and challenges of automation in the hospital pharmacy, are we one step closer to matrix or will hospital pharmacists have more quality time to do their job? The final Synergy Satellite ‘The essentials of biologicals – past, present and future’ (sponsored by an educationalal grant from Sandoz) will take place on Thursday at 16:30 and Friday at 9:00 and will examine the development, authorisation procedure and quality criteria of biologicals, reviewing their economic impact and safety concerns.

This year’s three keynote presentations will offer you excellent information on future demographic and disease trends and challenges, the opportunities of the hospital pharmacy practice and the need to adequately market the profession in order to attain the best results for patients. So, get ready for a positive atmosphere and a welcoming spirit at this year’s Congress, and don’t forget to meet all the interesting speakers, participants and EAHP staff!

EAHP will continue to advocate on behalf of the hospital pharmacist and we hope this year’s event exceeds your expectations!

Jennie De Greef – EAHP Chief Operating Officer

Jennie De Greef EAHP Chief Operating Officer

EAHP warmly thanks our industry partners for their continued commitment to supporting the goals of hospital pharmacists.

CORPORATE PARTNERS PLATINUM PARTNERS

OTHER SPONSORS

23rd Congress of the EAHP

4

KEYNOTE 1: PREVIEW & SPEAKER BIO

Global health and infectious diseases – Advice by Helena Nordenstedt responsible for approximately half of all deaths caused by infectious diseases each year have shifted out of the focus of the public eye. To counteract this development, Helena Nordenstedt, Public Educator at Gapminder and Assistant Professor in Global Health at Karolinska Institutet, will open this year’s Congress of the European Association of Hospital Pharmacists (EAHP) with a session on global health trends and demographic forecasts.

Before the opening ceremony, EAHP asked Mrs Nordenstedt a few questions about her presentation and its overall aim.

The insights and advice she shared with us were collectedvia a small interview.

At the 23rd Congress of the EAHP, you will take hospital pharmacists on a journey to explore a fact–based view on global health and infectious diseases. What advice would you give to hospital pharmacists to help them better understand the ongoing global disease panorama shift?

as gate keepers, to ensure drugs are being used appropriately. For example to help in the fight against antibiotic resistance – to stop drugs from being sold without control and used senselessly. Pharmacists are usually the last person a patient meets before going home, managing their own drug therapy, and often the only one who talks to about drugs and their effects. I will in my talk touch on the Sustainable Development Goals of the UN (Agenda 2030).

There it’s clear that all health care professions need to come together to reach the goals.”

With her presentation Mrs Nordenstedt hopes to provide Congress participants with more accurate and fact based knowledge on global development in general and the global disease panorama shift in particular. The demographic forecasts that will be shared should help hospital pharmacists understand the ongoing global shift as well as the worldwide demographic trends until the year 2100 and their underlying reasons.

Ulrika Gillespie – EAHP Scientific Committee Member

M

Helena Nordenstedt Public Educator & Assistant Professor

ajor advances have been made in reversing the spread of infectious diseases since the adoption of the Millennium Development Goals (MDGs). To carry on the momentum generated by the MDGs, the United Nations (UN) decided to continue focusing on infectious diseases as one of the key areas among its 17 Sustainable Development Goals (SDGs) for 2030. Universal health coverage, access to quality essential health–care services and access to safe, effective, quality and affordable essential medicines as well as vaccines for all are the targets of the third SDG which tries to ‘ensure healthy lives and promote well–being for all at all ages’.

However, despite the advances of the MDGs and the SDGs, headlines have focused over the past year’s on infectious diseases, such as Ebola Hemorrhagic Fever or West Nile Virus, which affect only a relatively small number of people worldwide. While tuberculosis, malaria, and AIDS which are

“To stay up–dated! To remember that nothing is static, everything in the world changes, and what you think you know to be a fact or what you learnt in school is not necessarily true anymore. Nowadays, children survive childhood and in adulthood they risk other diseases; cancer, heart–disease, mental health issues. No longer diseases of poverty but chronic diseases.”

As teacher and educator in the field of global health what was the biggest challenge that you faced in teaching this subject?

“The biggest challenge is that many students are convinced they already know the facts, so when I tell them somethings they won’t believe me! Younger people are usually more flexible though, more prone to take in new things and ideas and many are very interested and engaged.”

What kind of role should global health play in the education of pharmacists?

K E Y N OT E

1

H ALL C Wednesd ay 21 March 8.30 – 10.1 5

“Pharmacists have vital roles in global health – for example

New this year This year’s new and exciting developments include; the Synergy Masterclass on ‘Leadership and Management’, the Self–Assessment Tool (SAT), the Statement Implementation Learning Collaborative Centres (SILCC), new features for our Congress App and the Fun run!

Synergy Masterclasses This upcoming October 2018, EAHP will have the pleasure of presenting its first Synergy Masterclass sponsored by Amgen, where the themes of leadership and management will be explored. The two–day event will feature seminars by experts as well as workshops in which participants are encouraged to share their unique experiences. A follow up course to this masterclass will take place in 2019 with the topic of ‘Procurement, Tendering and the Decision Making Process in the Hospital Setting’. EAHP is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education, and the main goal of the Synergy Masterclass is to develop leadership and management skills essential for all qualified healthcare professionals, regardless of their position. Join us this fall and hone your skills!

Self–Assessment Tool This Congress marks the launch of the Self–Assessment tool, an online tool allowing hospital pharmacists to assess the level of Statement Implementation within their hospitals. The tool will also provide the means for hospital pharmacists to address the areas needing improvement with a tailor–made action plan and evidence–based resources. Come to EAHP Booth #78 to learn more about the tool and the European Statements of Hospital Pharmacy!

Statement Implementation Learning Collaborative Centres (SILCC) Another exciting initiative being launched this congress is the SILCC programme. This programme will allow hospital pharmacists (SILCC Fellows) to visit hospitals (SILCC Hosts) from other EAHP member countries while learning about pharmacy procedures linked to the European Statements of Hospital Pharmacy. EAHP will provide

limited financial help to SILCC Fellows and a reward system for SILCC Hosts. Visit www.statements.eahp to learn more about the SILCC programme and don’t forget to visit the EAHP Implementation team at the EAHP Booth #78!

Congress App This year our congress app has had a makeover, for which we would like to thank Bayer for their sponsorship. Discover the newly redesigned programme agenda, which makes for easy navigating through this year’s content, so you don’t miss out on your favourites! Use the new matchmaking feature to find other delegates with similar interests, and network easily by sharing your contact information via the business card request. All of this and more, with a dynamic activity feed with the latest news, and the chance to share your comments, experiences and special moments.

Enjoy the future of mobile congress connectivity!

Fun run This Friday 23rd March at 7:00, brave hospital pharmacists will jog through Gothenburg…for a great cause! The cultural run is aimed at supporting children with cancer and is organised by Children’s Cancer Netherlands (KiKa). The itinerary will be 5km through the city highlights and will be at a slow pace, so everyone can enjoy the views! Participants are asked to meet at 7:00 at Svenska Mässan, the Swedish Exhibition & Congress Centre, and bring their running shoes and a 10– euro contribution. Please contact Berry van Schaik for preregistration and payment at kikarun@xs4all.nl. And remember… runners will get a white running jacket as a souvenir!

Jennie De Greef – EAHP Chief Operating Officer

23rd Congress of the EAHP

5

SYNERGY EVENT: PREVIEW & SPEAKERS

Biosimilars in breast cancer – the next challenge

I

s there anything new about Biosimilars? It seems that everything has been said and explained. And what’s new about breast cancer? We all know it is a terrible disease, but one where progress in early diagnosis, surgery, radiotherapy and medicinal products has changed (for the better) the lives of millions of patients with this disease.

So why do we need a seminar about Biosimilars in breast cancer? What is the “next challenge”?

Let’s look at the facts.

when used in the adjuvant setting has a curative intent, so the stakes are really high, and there is really something new to talk about.

Fact two: Although breast cancer diagnoses and treatments have improved dramatically in the last decades, there are still unmet needs and new drugs are steadily coming into the market with a promise of better clinical outcomes and a certainty of increased costs.

So, the challenge is how to accommodate new costly treatments and how trastuzumab Biosimilars fit into the picture.

Fact one: Although several Biosimilars have reached the market in many areas, only one has been approved recently in cancer therapy, rituximab, and this is only for onco– haematology. The expected approval of trastuzumab Biosimilars in 2018 will be a first in what concerns solid tumours. And it cannot be forgotten that trastuzumab,

First, we will look again at Biosimilars, but with a specific focus on trastuzumab: from quality to clinical development, what’s the process for approval of these medicinal products in Europe.

EAHP POLICY ARTICLE

New Medical Devices Regulations – Preparation is key

M

edical devices include a wide array of products ranging from simple plasters to prostheses or pacemakers. They play a central role in maintaining health and quality of life of the population. Three Directives that were adopted in the 1990s currently regulate medical devices, active implantable medical devices and in vitro diagnostic medical devices.

Technological and scientific progress, recent scandals, greater transparency for patients as well as the traceability of the products triggered a review process by the European Commission in 2012.

• •

•

•

• Unlike medicinal substances, medical devices do not need a pre–market authorisation before being placed on the market. Instead, medium and high–risk devices need to pass a conformity assessment, performed by an independent third party, the so–called ‘notified body’.

Improvements that have been made to modernise the current system will not meddle with these principles.

However, they will significantly improve the certification and control of medical devices to rebuild patient trust in the robustness of the EU approach.

•

• • •

Even though the regulatory framework was not completely overhauled, the European Commission decided to replace the existing three Directives by two Regulations dealing with medical devices and in vitro diagnostic devices. Weaknesses, such as differences in Member States’ interpretation and application of rules, as well as regulatory flaws and gaps in regard to certain devices, such as for instance certain aesthetic devices, are addressed by the texts of Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices through the following improvements: •

Widening and clarifying the scope of the legislation, including for example, aesthetic implants and medical software;

Ensuring a closer supervision of the notified bodies by the national authority; Offering more responsibility and authority to the assessment bodies, including regular checks on manufacturers and thorough testing; Installing a new risk classification system for in vitro diagnostic medical devices in line with international guidance; Clarifying the rights and obligations of the parties involved in the supply chain, covering also internet sales and diagnostic services; Ensuring transparency to patients and healthcare professionals through a database (EUDAMED) containing comprehensive information about the devices available on the EU Market; Introducing a Unique Device Identification system (UDI system) to ensure post–marketing surveillance and traceability; Implementing stricter requirements for clinical evidence; Adapting the safety and performance requirements to new health technologies; and, Enhancing coordination between national surveillance authorities and aligning to international guidelines to facilitate trade.

The new Regulations will ensure a consistently high level of health and safety protection for EU citizens using these products as well as a uniform application of medical device legislation throughout the Union. They will gradually be implemented over the next years, with the process ranging from 3 years for medical devices to 5 years for in–vitro diagnostic devices.

To facilitate this process, the European Commission’s Directorate–General Internal Market, Industry, Entrepreneurship and Small and medium–sized enterprises (DG GROW) is planning to publish a number of guidance documents in 2019, including also one

Then we will look at the clinical concerns about the use of Biosimilars, including issues such as extrapolation of clinical trial data and switching from reference to Biosimilars in the middle of treatment.

Finally, we will listen to the oncologist, who will focus on what’s new in breast cancer therapy and what his feeling about the use of trastuzumab Biosimilars.

But the key for the success of this seminar is final debate, involving the experts and the audience. This is where YOU come in. Very soon, people in your hospital will be asking you questions about this, so come to this seminar, involve yourself in the debate, and be ready for the next challenge!

António Gouveia – EAHP Scientific Committee Member

The EAHP

Daily dose Check the electronic version!

All congress participants have now the opportunity to see in advance what is in the congress newspaper the Daily Dose.

Stay tuned to your mailbox!

n the i e g a t Eng bate a e d r e Twitt

18

P #EAH

targeted at hospital pharmacists. Since preparation for the implementation of the new Regulations is key, the European Association of Hospital Pharmacists (EAHP) will be working very closely with its members and DG GROW to ensure that the hospital pharmacy guidance document on medical devices covers all open questions and aspects important to the profession.

Hospital pharmacists interested in the topic of medical devices should also consider attending Seminar PQ1: Materiovigilance (UDI – tracing – reporting) on Thursday, 22 March 2018 (9:00am to 10:30am) or Friday, 23 March 2018 (9:00am to 10:30am) held in room F5.

Stephanie Kohl – EAHP Policy Officer

23rd Congress of the EAHP

6

SYNERGY EVENT: PREVIEW & SPEAKERS

Anticoagulation – from theory to practice

T

here has been a true revolution for patients suffering from atrial fibrillation in the past ten years. This is particularly related to the introduction of DOACs (Direct Oral anticoagulants) on the market that completely changed the therapeutic strategies.

For the last two years, at each EAHP conference the synergy symposium on anticoagulants were the most attended ones highlighting the major interest for the pharmacists.

The hospital pharmacist is now fully aware of the important role in educating patients on oral anticoagulants as well as in their management in ensuring the appropriateness of therapy. This year, for the new synergy symposium on anticoagulants entitled Anticoagulants from theory to practice, we will have three acknowledged speakers being part of IPACT (International Pharmacists for Anticoagulation Care Taskforce). They will present projects elaborated by pharmacists that contribute to a better care of patients suffering from atrial fibrillation (AF).

and ask for any risk factors or undesired symptoms, altogether supplemented with a medication review. Concerning AF, pharmacist can check the pulse to detect any abnormalities in the heart rate.

What are the main messages you could share with us from of pharmacists experiencing some screening campaign?

All around the experience from pharmacists involved in the campaign seems to be positive as the pulse check could be easily implemented in many pharmacies. The awareness campaign also showed that pharmacists can successfully raise the general population’s knowledge of AF. On the other hand, the collaboration with physicians to increase awareness about this role of pharmacists is still needed.

KATERINA MALA:

What is the required knowledge and skills listed by IPACT for the pharmacists to develop pharmaceutical for anticoagulated patient?

The IPACT working group have developed guidelines about these issues using a Delphi approach amongst multi–disciplines including cardiologists/ external clinical pharmacists /general practitioners/nurses. Following the patient pathway, there are clear opportunities for pharmacists to interact and intervene with the patient to ensure safe and effective care is provided. For this we need to ensure pharmacists are fully prepared.

What are recommended or suggested training pathway to get a competent clinical pharmacists ?

We recommend to associate theory and practical case

Could you tell me why pharmacists can contribute in improving the screening of AF patients?

Well, pharmacists are one of the key and most easily accessible health care professionals in primary care. Therefore they should be responsible for ensuring patients receive the most appropriate counselling about their treatment; but also they can support undiagnosed and untreated patients by becoming engaged in early detection in partnership with other healthcare providers. Prevalence of AF is increasing, and pharmacists can identify the risk of AF prior to the physicians’ visit.

How can they proceed to do so?

Pharmacist has a great opportunity to interview the patient

STEPHANE STEURBAUT: Ensuring the pharmacy profession has the knowledge and skills to manage patients receiving anticoagulation

GOTHENBURG INFORMATION

Things to do in Gothenburg

S

weden’s second city is an authentic, sophisticated Scandinavian destination, boasting an eclectic blend of heavy industry, neoclassical architecture and a burgeoning contemporary arts scene. In fact, Gothenburg has recently gained a top 5 position amongst attractive European cities.

Haga is Gothenburg’s most historic and charming district. With its 19th century wooden houses, saved from demolition in the 1970s, you will lose yourself in the cobbled streets lined with small stores with character and cosy cafés for a delightful caffeine fuelled afternoon stroll. Among Gothenburg’s industrial landmarks are the Volvo museum and the iconic Älvsborg bridge, which connects the northern and southern halves of the city. Do not forget to view the unique collection of Nordic art at the Museum of Art and enjoy Gothenburg Symphony Orchestra at the Concert Hall. Gothenburg is abundant in parks.

Slottsskogen is a 137–hectare haven in the middle of the city, with playgrounds and picnic spots, as well as a year–round free zoo. A 30 minute tram ride will take you from the city centre to Saltholmen, right on the edge of the islands of Gothenburg’s archipelago, where you will forget you’ve come from the city. Fishing was once the city’s most important industry. Feskekôrka – quite literally translated as “fish church” is a Gothic inspired fish market and Gothenburg’s best place to find loaves and fishes.

To learn more about the large variety of venues and sightseeing opportunities offered by Gothenburg, please visit www.goteborg.com.

including real patient role play.

What are the educational materials available to assist the pharmacists in their training ?

An e learning module was designed which will be available soon for all of us. This was piloted at the recent ESCP conference where feedback was extremely positive and we plan to develop more modules to support pharmacists in their training.

BART VAN DEN BEMT: What are the success factors to ensure that your anticoagulated patient received a continuity of Pharmaceutical Care?

If there was only one to consider, I would say a good communication between transfer of care ie from the hospital back to the community highlighting the integral role the hospital pharmacist can play in communication to the GP, the patient and his/her possible caregiver and to the community pharmacist Other considerations that were prominent were supporting adherence, and the importance of medicines reconciliation and medication review.

What are the successful experiences of Integrated care so far that could be reproduced?

There are a lot of initiatives all around Europe launched by different pharmaceutical team. For example, as said earlier the AF screening by pharmacist or the combination of medication reconciliation and anticoagulant consultation to facilitate seamlesscare of anticoagulated patients.

André Rieutord – EAHP Scientific Committee Member

23rd Congress of the EAHP

7

STATEMENT IMPLEMENTATION

From a vision to a reality: implementing the European Statements within EAHP member countries

A

l ot has hap p e n e d sin ce th e St ate m e nt Implementation project was launched during the 22nd EAHP Congress in Cannes (March 2017). The EAHP Implementation team has been working alongside national associations and the network of national implementation ambassadors to promote the implementation of the European Statements of Hospital Pharmacy within all 35 EAHP member countries.

implementation of the

european statements of hospital pharmacy

right for the patient, right for the profession

One of the priorities for EAHP is to understand the needs and priorities of the national associations when it comes to Statement implementation. Therefore, the EAHP Implementation team organised several workshops during the last EAHP General Assembly in Malta (June 2017) to collaborate and come up with ideas for the next steps of the project. An update of the strategic implementation plan was put together after taking into account the feedback from our members. EAHP has already progressed numerous items included in the updated strategic plan: from updating our awareness campaign to designing national implementation strategies. All relevant information about the project, including all progress made, can be found on our website: www.statements.eahp.eu

This Congress will see the launch of two exciting EAHP initiatives: the online Self–Assessment tool (SAT) and the Statement Implementation Learning Collaborative Centres programme (SILCC).

to visit hospitals (SILCC Hosts) within other EAHP member countries to learn about pharmacy processes linked to the European Statements of Hospital Pharmacy. EAHP will be providing some limited financial help to SILCC Fellows and a reward system for SILCC Hosts.

silcc

Participants who visited the EAHP Booth in Cannes last year were able to test the alpha version of the self–assessment tool and now EAHP is launching its final version. By assessing their hospital pharmacies, hospital pharmacists will not only be able to understand the statement implementation level within their hospitals but also understand where they are in comparison with hospital pharmacies in their own countries and also other EAHP Member countries. The self– assessment tool will also complement the information collected through EAHP’s regular surveys.

The tool will provide the means for hospital pharmacists to address the areas needing improvement with a tailor–made action plan and evidence–based resources. The tool is already translated into several languages and can be found at: http://sat.eahp.eu/en/home

sathp Self-assessment tool for hospital pharmacists

Statement Implementation Learning Collaborative Centres

As in previous years, you will find at this Congress that all educational activities, presentations and posters have been linked to the European Statements.

Do you want to learn more about the European Statements of Hospital Pharmacy and the implementation project?

Do you want to test the self–assessment tool and learn more about the SILCC programme?

Come and meet with the EAHP Implementation team at Booth #78 in the exhibition area.

EAHP Implementation Team

EAHP is also launching the SILCC programme. This programme will allow hospital pharmacists (SILCC Fellows)

KEYNOTE 2: PREVIEW & SPEAKER BIO

EAHP photo corner

We have a dream!

L

ife for the hospital pharmacist is not easy. Challenges are always new and demanding, resources are always scarce, and problems always seem to be too many.

You sometimes feel like being stuck in a video game; as soon as you get rid of an enemy, another one appears, tougher than the previous one, and it seems there is always yet another level to pass.

So how can we deal with this? Maybe the first step is to look back and reflect; where do we come from, what have we achieved, where are we now? By doing so, we can look into the future and see the different paths ahead of us.

And this is what this seminar is all about, looking for lessons from the past, feeling the present as it is and

Cheryl McKay Managing Director

Shoot it

means that something else will be lacking in the healthcare scenario.

K E Y N OT E

H ALL C

2

Thursday 22 March 11.00 – 12 .00

So come to this seminar, share our dream, and maybe someday it will come true. Or maybe you have a different dream, and the seminar might give you inspiration on how to fulfil it. Either way, what really matters is that hospital pharmacists improve patient care. That is what we are supposed to do, that is our common dream.

Share it Hashtag it instagramphotoopLINES.pdf

1

10/03/2018

09:55

EAHPofficial

FOLLOW

António Gouveia – EAHP Scientific Committee Member

how it came to be, and charting paths for the future.

C

M

Y

CM

MY

CY

CMY

K

We may dream about a future where hospital pharmacists will still be pharmacists, with all their scientific knowledge about medicines, but will have an ever more enhanced focus on the patient. Even when they are involved in more traditional areas, such as compounding, they will think more about patient outcomes. But they will surely be full members of the therapeutic team, making sure that the use of medicines is taken to their very best, ensuring safety, efficacy, and also efficiency.

Yes, efficiency, because in a world of scarce resources, and with rising costs of medicines, choices must be made, as a non–efficient use of medicines

3500 Hospital pharmacists - Show us what you can do! #23EAHPCongress #EAHP2018

The EAHP photo corner is located next to the Cyber Café Jonathan Underhill Medicines Consultant Clinical Adviser

23rd Congress of the EAHP

8

SURVEY RESULTS

2017 EAHP Statements Survey The 2017 EAHP Statements Survey was conducted last year with the focus on:

should be part of undergraduate and postgraduate training programmes for hospital pharmacists.

Section 2: Selection, Procurement and Distribution Section 5: Patient Safety and Quality Assurance Section 6: Education and Research

The 5 questions with the lowest proportion of positive responses: QUESTION

PERCENTAGE OF PARTICIPANTS GIVING A

34 countries participated. The response rate of the survey was over 17,4 %, with 970 responses. We received response rates over 50 % from 10 countries and 9 countries had response rates between 30–50%. When asked “Which three statements are the highest priority for you to implement first?” the respondents indicated:

POSITIVE RESPONSE TO THE QUESTION S6.4

The pharmacists in our hospital routinely publish hospital pharmacy

30.3%

practice research S5.5.2

Our hospital pharmacy uses computerised decision support to reduce

45.2%

the risk of medication errors

2.1 Hospital pharmacists should be involved in the complex process of procurement of medicines. They should ensure transparent procurement processes are in place in line with best practice and national legislation.

2.6 Hospital pharmacies should have responsibility for all medicines logistics in hospitals.

This includes proper storage, preparation, dispensing, distribution and disposal conditions for all medicines, including investigational medicines.

5.5 Hospital pharmacists should help to decrease the risk of medication errors by disseminating evidence–based approaches to error reduction including computerised decision support.

The Statements most challenging to implement were: 5.5 Hospital pharmacists should help to decrease the risk of medication errors by disseminating evidence–based approaches to error reduction including computerised decision support.

5.11Hospital pharmacists should support and implement systems that allow traceability of all medicines dispensed by the pharmacy 6.4 Hospital pharmacists should actively engage in and publish research, particularly on hospital pharmacy practice. Research methods

Visit the Cyber Cafe!

Fill in the online evaluation forms of the sessions you attend to be part of the prize draw for free registration for the next EAHP Congress

FREE WI–FI SERVICE WILL BE AVAILABLE THROUGHOUT THE CONGRESS CENTRE AND IN THE CYBER CAFÉ SPONSORED BY

S6.4.4

Have you or your pharmacists engaged in development of local/

50.1%

national guidelines?

S2.5.2*

Have you had reason to contact the medicines authority in your coun-

59.8%

try because of medicines shortages?

S5.7

The medicines administration process in our hospital ensures that the

63.2%

transcription steps between the original prescription and the medicines administration record are eliminated

* For question S2.5.2: 59.8% of responses specified that they had reason to contact the medicines authority

The statistical evaluation of the data is still ongoing, but we can presume, based on what was already analysed, that overall implementation of the Statements in Sections 2,5,6 have not improved much in the past two years, but it is a very short period to show a significant increase in the implementation levels. On the other hand, we see a steady increase in the Statements’ awareness level among hospital pharmacists, which is key for implementation.

Capacity and capability, in some cases, seem to remain the main barriers. Our capacities are more often spent for instance on drug shortages rather than the implementation process.

The complete survey results will be available to members shortly. A comprehensive analysis will be published to the European Journal of Hospital Pharmacy.

Petr Horák – EAHP President–Elect

KEYNOTE 3: PREVIEW & SPEAKER BIO

Marketing the hospital pharmacist profession

O

n Friday at 11am, during the final morning of the EAHP Congress, participants will receive a boost to their outreach and marketing skills via an engaging presentation on marketing the hospital pharmacy profession. Ms Catherine Pic ton (BSc, MBA , FRPharmS), Professional Secretary to the Royal Pharmaceutical Society (RPS) Hospital Expert Advisory Group and independent health and policy consultant, will raise our awareness of these meaningful issues. Most professionals understand the importance of their daily activities, as well as the added value they bring to their organisation or field as a whole, but this understanding isn’t always shared by the broader public, or even by their co–workers or managers. Why are hospital pharmacists important for the smooth operation of a hospital? If we know the answer, everyone involved should know it as well, and this is where marketing enters the equation.

Hospital pharmacists have traditionally focused on their professional activities, often neglecting the active marketing of their profession as unnecessary or simply not within their skillset.

However, marketing the profession is important not only for hospital pharmacists, health care professionals and patients, but also for the overall provision of hospital services. If you wanted to send a rocket to space, any

engineer could help, but an aerospace engineer should point out that they are especially suited for the job! While we know our contribution to patient safety through our education, competencies, abilities and know–how, not everyone does.

What strategies can be used to strengthen the role and decision– making capacities of hospital pharmacists within their hospital? Possibly the profession should be marketed more broadly, maybe with a catchy slogan or even with door–to–door promotion? In this regard, there are many questions to answer on the way to appropriately market the hospital pharmacy profession, including who to target, what the tactic should be and what tools should be used. Other

K E Y N OT E

H ALL C

3

Friday 23 March 11.30 – 13 .00 professions within the hospital environment have already advocated for their role, including specialised nurses and physicians, so it is time for hospital pharmacists to rise to the challenge!

A hospital can only offer excellent services through the cooperation and involvement of all health care professionals, which means promoting ourselves is crucial. Luckily, the final Keynote of this year’s EAHP Congress in Gothenburg will introduce a variety of creative approaches to do just that!

Catherine Picton Healthcare and policy consultant

Jordi Mallarach – EAHP Policy Team Assistant

23rd Congress of the EAHP

9

SYNERGY EVENT: PREVIEW & SPEAKERS

Biosimilars in cancer care – the next challenge

B

iosimilars of blockbuster antineoplastic drugs that are key therapeutic options in several types of cancer will be coming to the market soon, such as rituximab, cetuximab or trastuzumab. The opportunity for savings is huge, biological drugs may account for half the cancer drugs budget, but these drugs will be used in life threatening diseases and this may lead to some concerns. To make the best of this new frontier, hospital pharmacists must understand the concepts and facts, to be able to provide a scientific, unbiased approach to this issue, with a focus on patient care in a world of limited resources.

EAHP invited three excellent speakers Dr. Rosa Giuliani, Dr. Paul Cornes and Dr. Gustaf Befrits to elaborate on the role of biosimilar medicines in cancer care. Dr. Rosa Guliani will present the clinician’s perspective in prescribing biosimilars based on their own clinical experience and the position paper ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’, which was published in November 2017.

Dr. Rosa Giuliani is a consultant in medical oncology at the Oncology Department of S. Camillo–Forlanini Hospital in Rome, Italy. Since 2012 she is a core member of the European Medicines Agency’s (EMA) scientific advisory group in oncology. Since 2012 Dr Giuliani serves the European Society for Medical Oncology’s (ESMO) Public Policy Committee and on behalf of ESMO participates to the activities of the EMA Healthcare Professional Working Party (HCPWP), with the main interest to strenghten the collaboration between the academic and regulatory worlds. Since the end of 2013 she represents ESMO in the Stakeholder Forum of EUnetHTA (European Network for Health Technology Assessment).

Dr. Paul Cornes will present insights into the regulatory assessment process of biosimilars. In his presentation he will discuss, e.g. how confident oncologists and haematologists in Europe and the USA have been in recommending that cancer patients can safely use a biosimilar version of a therapeutic cancer biologic medicine such as trastuzumab or rituxumab, when to switch a cancer patient from a reference biologic to a biosimilar – how great the risk of an increase in

adverse events is, how biologic medicines should be named when prescribing in Europe. Dr. Paul Cornes (BM BCH) is oncologist in Bristol, UK. He is working for the Comparative Outcomes Group.

Dr. Gustaf Befrists will discuss un his presentation the impact of biosimilars on affordable cancer care with focus on trastuzumab, bevacizumab and will discuss which substance will most probably have the more rapid price decreases in oncology care. Dr. Gustaf Befrists is health economist in Stockholm, Sweden.

The Synergy satellite event ‘Biosimilars in cancer care – the next challenge’ will contribute to hospital pharmacists needs to have insights into clinician’s perspectives in prescribing biosimilars, into the regulatory assessment process and impact of biosimilars on affordable cancer care.

Juraj Sykora – EAHP Scientific Committee Member

Untitled 1

2

3

Crossword Puzzle

4

5

Complete one of the crossword puzzles included in the Wednesday and Thursday Daily Dose, bring it to the EAHP booth #78 and enter a prize draw to win a free registration for the 24th EAHP Congress in Barcelona (27 – 29 March 2019).

6

ACROSS

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

23

22

24

2. What association brings together pharmacy students from all over Europe?

6. The ADKA Drug Information Database is available in German, English and…?

8. This little robot at booth 23 helps you to explain atrial fibrillation to patients 10. You can find the answer at booth number 57. Ask James!

12. IMI’s products are an example of this?

13. Which inspection is JVM Europe showing on the exhibition?

14. EAHP initiative allowing hospital pharmacists to experience new work environments and practices in another hospital.

18. What product is being displayed in booth 63?

19. AwARe of Bayer’s innovative tool for HCPs, patients and cARregivers?

21. In which city NewIcon was founded? Find us at Stand 4.

22. This is at the core of section 5 of the European Statements of Hospital Pharmacy.

23. Number of languages KabiHelp’s software system is currently available?

24. What is the name of the product that can electronically secure cold chain medications by line item? Check the inside of the fridge in Booth Number 50.

DOWN

1. On the EAHP website, there is a section that includes good practices from around our member countries, what are they called?

3. Name the surveillance tool from Pfizer? The answer is at booth #1b!

4. In what month were the Mobility Survey results presented in Brussels?

5. What is the new product of Macopharma ? Booth 42 7. The next EAHP survey will be on which topic?

9. Highly similar versions of currently existing biologics..

11. Name of best new technology to stop medication errors at the bedside.

15. Booth 18 – One click is all it takes.

16. Suggest a tool to create a safer working environment 17. Artificial intelligence technology is coming soon to which evidence–based CDS solution? Visit booth 62 to find out!

20. The main task of the Common Training Framework Working Group 2 was a…?

24. Sponsor for Symposium on treating resistant pseudomonas March 22, 09:00

FULL NAME: EMAIL:

23rd Congress of the EAHP

10

TAKE PART IN THE BAYER MEET–THE–EXPERT SESSIONS Hall B – Booth no 26 Wednesday 21st March 10.45 – 11.15 How NOACs have changed VTE treatment in clinical practice.

What changed with EINSTEIN CHOICE? Paolo Prandoni 13.45 – 14.15 Practical Aspects of NOAC treatment to consider in multimorbid AF patients Sharron Gordon

Thursday 22nd March 13.45 – 14.15 How NOACs have changed VTE treatment in clinical practice.

What changed with EINSTEIN CHOICE? Paolo Prandoni 14.15 – 14.45 Practical Aspects of NOAC treatment to consider in multimorbid AF patients Sharron Gordon

STUDENTS

Student Programme

EAHP–EPSA Internship Platform: Increasing the visibility of Hospital Pharmacy among students

T

he EAHP–EPSA Internship Platform was launched in 2012 as a collaboration between the EAHP and the European Pharmaceutical Students’ Association (EPSA).

Its purpose is to offer a possibility for students to experience hospital pharmacy while they are still studying, or are young professionals. Currently, there are 21 hospitals available to students, from 8 different countries.

With the Internship Platform, EAHP and EPSA are working towards fulfilling the goal of the European Statement of Hospital Pharmacy, in particular of Statement 6.1 which sets out the following: “Undergraduate pharmacy curricula should include experience of hospital pharmacy practice.

The role of all hospital healthcare practitioners, including hospital pharmacists, should be integrated into the curricula of other health professionals.”

The demand for internship placements is high, in the year 2017, we had 24 students applying, and received 54 applications. The interest in the internship placements is rising since the platform was launched. Currently, plans are being formed on how to develop the platform further to offer more internship places to interested students that successfully undergo the application process.

Raphaela, an Austrian student, recently finished her internship at the Centre Hospitalier Universitaire Felix Guyon, located in St. Denis, Reunion Island, France. She agreed to share some insights on her experience.

How has the internship affected your perception of pharmacy/hospital pharmacy?

Raphaela: “In hospital pharmacy I got the feeling that you can use much more of all the knowledge acquired during the studies. There was a good communication basis between the pharmacists on various problems of all different sectors. At the pharmacy where I spent my internship, clinical pharmacy and patient visits where only at a trial stage, so I missed a little bit the contact with the patient. That might be an advantage

of the public pharmacy.”

In what way would you say the internship complimented your education in pharmacy, did you feel it did?

Raphaela: “It was interesting to see which parts of the studies are actually used in professional practice. Although you learn a lot about drug interactions during your studies, the application in “real” patient’s cases can differ concerning the risk–benefit ratio.”

In general, did you like the internship? What did you like the most?

Raphaela: “Yes, I could really benefit a lot from the internship. I had the chance to see a lot of different sectors in which pharmacists are working, and I learned a lot. Besides that, I was able to improve my French. I liked the most the open and welcoming nature of Réunionese people, not only at the hospital pharmacy but on the whole island.”

Raphaela enjoyed her internship very much. It helped her form an opinion about hospital pharmacy and to learn more about her own future goals. Among the primary reasons for choosing the hospital on the Reunion Island was her interest to improve her language capabilities. Being able to speak multiple languages will make professional mobility easier in the future, should she wish to pursue it. Moreover, she is not the only pharmacy student that gained positive experiences from the internship – there are many others.

The hospitals are happy with the interns as well. A number of them have been actively participating in the programme for several years already.

If your hospital pharmacy would be willing to host an intern from a different European country for up to three months and help them get an overview about the experience and skills they will need to work in a hospital pharmacy, check out how to get involved at the 23rd EAHP Congress, booth 78 or

WEDNESDAY 21 MARCH 14.30 – 18.30

An evidence based approach to developing an individualised patient care plan As part of the pharmaceutical care process, the pharmacist needs to cooperate with the patient and other members of the multi–disciplinary team to design, implement and monitor a therapeutic plan.

In the session, you will learn how to plan and conduct a patient drug history review, critically appraise different sources of information, and how data gathering fits in the systematic approach to pharmaceutical care.

The session is aimed at students and young professionals – learn more about individualised healthcare plans and how to approach them.

on the EAHP website: ht tp://w w w.eahp.eu/students/ eahp–epsa–internship–platform/ how–can–your–hospital–get–involved. Črtomir Fleisinger – EPSA President

23rd Congress of the EAHP

11

Award nominee and GPIs oral presentations

A

•

At 10.30 on Wednesday, in room A4 and A3, 14 authors will explain their work in short presentations, which will each be followed by a Q&A session.

The Good Practice Initiative oral presentations group includes: (Room A3)

The Award Nominee oral presentations group includes: (Room A4)

•

Implementing a national portfolio of extemporaneous pharmaceutical preparations used in Danish hospitals

• • •

Algorithm to develop an essential drug list Computerized quality control of the tablet splitting process Establishing an active working group for pharmacists working within pediatric oncology and hematology in Sweden, Finland, Norway and Denmark Let’s diversify to guarantee access to the hospital pharmacist’s expertise: All good things come in fours!

re you too busy to review all of the posters? EAHP has made a selection and is dedicating two sessions to oral presentations by the authors of the top nominated posters.

• • • •

•

• •

Contamination of the blister packs by pomalidomide after use in clinical situation Linezolid dosing in patients with liver cirrhosis: standard dosing risks’ toxicity Relationship between daily dose frequency and adherence in chronic myeloid leukaemia Estimation of precision and accuracy of five population pharmacokinetics models of infliximab in patients with inflammatory bowel diseases Computerised physician order entry impact on medication errors in a paediatric unit Best practice of ward–based reconstitution in pediatric hospitals Becoming a hospital pharmacist: an observational cross–sectional study

•

on the educational pathways from students’ perspective Design and implementation of a pharmacy technician training programme to improve outpatient drug dispensing

• Involving patients in a workshop focused on communication skills: a proof of concept of experiential training for residents in hospital pharmacy

PERSONALISED HOSPITAL PHARMACY

Meeting the needs of every patient CALL FOR ABSTRACTS! Abstract submission opens 1st August 2018

VIEW THE GUIDELINES ON http://www.eahp.eu/Congresses/abstract CONTACT US congress@eahp.eu

Free Wi-Fi service will be available through the congress center. The Wi-Fi network name is “GothiaTowers”and no password is needed

Come along to applaud and benefit from your colleagues’ hard work and creativity!

27th - 29th March 2019 | Barcelona, Spain

During the review process, the award nominees will be selected and the presenting author of the nominated abstracts will be invited to give an oral presentation after which the final judging will take place. All abstracts must be linked to the European Statements on Hospital Pharmacy.

EAHP 2018 Available in app stores for IOS, Android devices and on the Web

Brought to you by Bayer, EAHP Platinum Partner

24 th EAHP Congress

Unit Dose Done Right

Unit Do se Bar Cod , ing, Pharma c Nursing y & Supply Experts !

• Ultraviolet Inhibitant • Moisture Resistant • Tamper-Evident • Cold Seal • 6 and 12-month Beyond-Use Dating • 1-D and 2-D Bar Coding • Flexible Label and Report Formatting • Multiple Sizes to Fit Your Meds and Storage Needs

Simple. Reliable.

Distributed in Europe by Pero’s PEROS LOGO

27/04/10

14:17

Page 1

Please see us at Booth #22

Lyon-France +33.478.627.713 www.peros.fr contact@peros.fr